Lee Tombs

898 citations

60 papers · 638 indexed · h-index 14

Impact in

Pulmonary and Respiratory Medicine top 5%
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
- Respiratory and Cough-Related Research
- Neonatal Respiratory Health Research
Physiology top 5%
- Asthma and respiratory diseases

Papers in ⓘ

Pulmonary and Respiratory Medicine 52
- Chronic Obstructive Pulmonary Disease (COPD) Research 47
- Respiratory Support and Mechanisms 22
- Inhalation and Respiratory Drug Delivery 11
- Respiratory and Cough-Related Research 11
- Pulmonary Hypertension Research and Treatments 4
Physiology 32
- Asthma and respiratory diseases 32

Co-authors: Ian Naya (25 shared papers)David A. Lipson (26 shared papers)Paul Jones (17 shared papers)Dave Singh (9 shared papers)William A. Fahy (4 shared papers)I. Boucot (16 shared papers)Rodger Kempsford (7 shared papers)Chris Compton (7 shared papers)
Journals: International Journal of COPD (7 papers)Respiratory Research (6 papers)Advances in Therapy (4 papers)Clinical Therapeutics (3 papers)Therapeutic Advances in Respiratory Disease (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Lee Tombs

59 papers receiving 630 citations

Peers

Countries citing papers authored by Lee Tombs

Since Specialization

Citations

This map shows the geographic impact of Lee Tombs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee Tombs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee Tombs more than expected).

Fields of papers citing papers by Lee Tombs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee Tombs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee Tombs. The network helps show where Lee Tombs may publish in the future.

Co-authors

The 25 scholars most cited alongside Lee Tombs, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lee Tombs Line = papers co-authored together Lee Tombs links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial Respiratory Research ·François Maltais, Leif Bjermer, Edward Kerwin, Paul Jones, Michael L. Watkins, Lee Tombs, Ian Naya, I. Boucot, David A. Lipson, Chris Compton, Mitra Vahdati-Bolouri, Claus Vogelmeier	2019	76
2	Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study Advances in Therapy ·Gregory Feldman, Ana R. Sousa, David A. Lipson, Lee Tombs, Neil Barnes, John Riley, Sadhana Patel, Ian Naya, Chris Compton, Bernardino Alcázar Navarrete	2017	72
3	Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol International Journal of COPD ·Dave Singh, M. Reza Maleki-Yazdi, Lee Tombs, Ahmar Iqbal, William A. Fahy, Ian Naya	2016	54
4	Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials Advances in Therapy ·M. Reza Maleki-Yazdi, Dave Singh, Antonio Anzueto, Lee Tombs, William A. Fahy, Ian Naya	2016	37
5	Long-term outcomes following first short-term clinically important deterioration in COPD Respiratory Research ·Ian Naya, Lee Tombs, Hana Muellerova, Christopher Compton, Paul Jones	2018	29
6	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects British Journal of Clinical Pharmacology ·Rodger Kempsford, Ann Allen, Joanne Bal, David Rubin, Lee Tombs	2012	23
7	Measuring disease activity in COPD: is clinically important deterioration the answer? Respiratory Research ·Dave Singh, Gerard J. Criner, Ian Naya, Paul Jones, Lee Tombs, David A. Lipson, MeiLan K. Han	2020	23
8	The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing Respiratory Medicine ·Rodger Kempsford, Amanda J. Oliver, Joanne Bal, Lee Tombs, Dean Quinn	2013	22
9	A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects Pulmonary Pharmacology & Therapeutics ·Dennis Kelleher, Lee Tombs, Andrew Preece, Noushin Brealey, Rashmi Mehta	2014	17
10	Influence of Renal and Hepatic Impairment on the Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Fluticasone Furoate and Vilanterol in Combination Clinical Therapeutics ·Ann Allen, Angela Davis, Kelly Hardes, Lee Tombs, Rodger Kempsford	2012	17
11	Triple Therapy of Umeclidinium + Inhaled Corticosteroids/Long-Acting Beta2 Agonists for Patients with COPD: Pooled Results of Randomized Placebo-Controlled Trials Pulmonary Therapy ·Thomas M. Siler, Edward Kerwin, Lee Tombs, William A. Fahy, Ian Naya	2016	16
12	Tolerability of Fluticasone Furoate/Vilanterol Combination Therapy in Children Aged 5 to 11 Years With Persistent Asthma Clinical Therapeutics ·Amanda J. Oliver, Sandi VanBuren, Ann Allen, Melanie Hamilton, Lee Tombs, Amir Inamdar, Rodger Kempsford	2014	15
13	Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis Pulmonary Therapy ·Bernardino Alcázar Navarrete, I. Boucot, Ian Naya, Lee Tombs, David A. Lipson, Chris Compton, Ana R. Sousa, Gregory Feldman	2018	14
14	Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials Pulmonary Pharmacology & Therapeutics ·Riju Ray, Lee Tombs, Ian Naya, Chris Compton, David A. Lipson, I. Boucot	2019	13
15	Safety, tolerability, pharmacokinetics, and pharmacodynamics of vilanterol, a novel inhaled long‐acting β‐agonist, in children aged 5–11 years with persistent asthma: A randomized trial Clinical Pharmacology in Drug Development ·Amanda J. Oliver, Sandi VanBuren, Ann Allen, Melanie Hamilton, Lee Tombs, Rodger Kempsford, Paul Y. Qaqundah	2013	13
16	Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis Advances in Therapy ·Ian Naya, Lee Tombs, David A. Lipson, Chris Compton	2018	11
17	Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study ERJ Open Research ·John Riley, Chris Kalberg, Alison Donald, David A. Lipson, Muhammad Shoaib, Lee Tombs	2018	10
18	Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial Respiratory Research ·François Maltais, Ian Naya, Claus Vogelmeier, I. Boucot, Paul Jones, Leif Bjermer, Lee Tombs, Chris Compton, David A. Lipson, Edward Kerwin	2020	10
19	Effects of Moderate Hepatic Impairment on the Pharmacokinetic Properties and Tolerability of Umeclidinium and Vilanterol in Inhalational Umeclidinium Monotherapy and Umeclidinium/Vilanterol Combination Therapy: An Open-Label, Nonrandomized Study Clinical Therapeutics ·Rashmi Mehta, Kelly Hardes, Dennis Kelleher, Andrew Preece, Lee Tombs, Noushin Brealey	2014	10
20	Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis Respiratory Research ·Ian Naya, Lee Tombs, David A. Lipson, I. Boucot, Chris Compton	2019	10

About Lee Tombs

Lee Tombs is a scholar working on Pulmonary and Respiratory Medicine, Physiology, Analytical Chemistry, Animal Science and Zoology and Biochemistry, having authored 60 papers that have together received 638 indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (47 papers), Asthma and respiratory diseases (32 papers), Respiratory Support and Mechanisms (22 papers), Inhalation and Respiratory Drug Delivery (11 papers), Respiratory and Cough-Related Research (11 papers), Pulmonary Hypertension Research and Treatments (4 papers), Analytical Methods in Pharmaceuticals (3 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (595 citations), Physiology (462 citations), Issues, ethics and legal aspects (10 citations), Emergency Medical Services (13 citations) and Emergency Medicine (17 citations). Lee Tombs has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Ian Naya, David A. Lipson, Paul Jones, Dave Singh, William A. Fahy, I. Boucot, Rodger Kempsford, Chris Compton, M. Reza Maleki-Yazdi and Edward Kerwin. Their work appears in journals such as International Journal of COPD, Respiratory Research, Advances in Therapy, Clinical Therapeutics and Therapeutic Advances in Respiratory Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact